Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Presentation TCT 2023

Addressing Microvascular Obstruction with SSO2

Presenter: Gregg Stone

October 25, 2023

Presentation TCT 2023

Bivalirudin Is the Most Evidence Based Antithrombin Agent for Primary PCI

Presenter: Gregg Stone

October 25, 2023

Presentation ESC 2023

Intravascular Imaging Guidance for PCI: A “Real-Time” Updated Network Meta-analysis

Presenter: Gregg W. Stone

August 28, 2023

Presentation THT 2023

5-Year COAPT Outcomes With MitraClip in FMR

Presenter: Gregg Stone

March 22, 2023

Presentation THT 2023

The PRELIEVE Trial: Responder Analysis in the HFpEF Subgroup Regarding Baseline PVR, Pacemaker and Pressure Gradients

Presenter: NULL

March 22, 2023

Presentation THT 2023

A Left Ventricular Transcatheter Repair Device for HFrEF Patients: FIH Experience With the Vsling Device

Presenter: Gregg Stone

March 21, 2023

Presentation THT 2023

Pulmonary Artery Denervation: Innovative Pulmonary Hypertension Therapies

Presenter: Gregg Stone

March 21, 2023

Presentation THT 2023

How Narrow or Broad Should Trial Enrollment Criteria Be to Achieve Clinically Interpretable Results? (STEMI vs NSTEMI; RV vs. LV vs. LV&RV Shock; AMI-CS vs Chronic HF-CS)

Presenter: Gregg Stone

March 20, 2023

Presentation THT 2023

Impella for Cardiogenic Shock: High Expectations From Ongoing Studies

Presenter: Gregg Stone

March 20, 2023

Presentation ACC 2023

5-Year Follow-Up After Transcatheter Repair of Secondary Mitral Regurgitation The COAPT Trial

Presenter: Gregg W. Stone

March 05, 2023

Advertisement

Addressing Microvascular Obstruction with SSO2

Bivalirudin Is the Most Evidence Based Antithrombin Agent for Primary PCI

Intravascular Imaging Guidance for PCI: A “Real-Time” Updated Network Meta-analysis

5-Year COAPT Outcomes With MitraClip in FMR

The PRELIEVE Trial: Responder Analysis in the HFpEF Subgroup Regarding Baseline PVR, Pacemaker and Pressure Gradients

A Left Ventricular Transcatheter Repair Device for HFrEF Patients: FIH Experience With the Vsling Device

Pulmonary Artery Denervation: Innovative Pulmonary Hypertension Therapies

How Narrow or Broad Should Trial Enrollment Criteria Be to Achieve Clinically Interpretable Results? (STEMI vs NSTEMI; RV vs. LV vs. LV&RV Shock; AMI-CS vs Chronic HF-CS)

Impella for Cardiogenic Shock: High Expectations From Ongoing Studies

5-Year Follow-Up After Transcatheter Repair of Secondary Mitral Regurgitation The COAPT Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content